Dheeraj Aggarwal

Containing aceclofenac, a non-steroidal anti-inflammatory drug (NSAID), Achnil is a pioneering product developed by the VMRC in its efforts to develop a controlled release formulation based on the novel drug delivery system.

Expect $100m revenue via Elores by FY18: Venus Remedies

In an interview to CNBC-TV18, Dheeraj Aggarwal, CFO, Venus Remedies spoke about revenue prospects of Elores, for which the company recently won patent from Japan.

Venus Remedies signs out-licensing pact; stock up 20%

Venus Remedies entered OTC (over-the-counter) category with Ezenus. Dheeraj Aggarwal, CFO, Venus Remedies says that Ezenus is our first OTC product which is a stress reliever. It works for reducing anti-toxicants in the body.

New OTC drug to garner Rs 25cr revenues: Venus Remedies

Dheeraj Aggarwal, CFO, Venus Remedies, speaking to CNBC-TV18 on the occasion of the company's first ever over-the-counter (OTC) stress reliving drug launch, said that it is a unique product with no competition.